MAP Pharmaceuticals

  • Pharma Buyout With a 60% Premium

    By Mike Thiessen - February 12, 2013 | Tickers: AGN, MAPP, MRK, PFE

    Irvine, California-based healthcare company Allergan (NYSE: AGN) has announced its intention to purchase Mountain View, California-based MAP Pharmaceuticals (NASDAQ: MAPP) in a complex tender deal valued at about $960 billion. The deal will involve the purchase of all of MAP's outstanding shares. Although the deal is subject to customary closing conditions like an antitrust investigation and dual shareholder vote, it appears unlikely that any issues will arise to delay more »

  • Can Map Pharma Cure Your Portfolio Headache?

    By Douglas Ehrman - November 26, 2012 | Tickers: AET, AGN, AMGN, MAPP, VVUS

    Shares of drug maker Map Pharmaceuticals (NASDAQ: MAPP) surged by over 20% during Friday’s abbreviated trading session. The catalyst for the move was the announcement that the U.S. Food & Drug Administration (FDA) had accepted the company’s resubmitted application for its migraine drug, Levadex.

    The news was obviously viewed as a significant positive by the market, but the question now becomes what to do with the stock moving more »

  • Is Bain Capital Betting Against Mitt Romney?

    By Meena Krishnamsetty - October 10, 2012 | Tickers: AMRN, IDIX, MAPP, PFE, VRTX

    As debate season heats up, we had an interesting takeaway from the first 2012 Presidential debate. Obama failed to mention anything about Romney’s old firm, Bain Capital. That is not going to stop us from mentioning it—in the issues that Romney and Obama did discuss, Romney continued to take the hardline that he would repeal Obamacare if elected.

    As mentioned, the fact that Obama failed to discuss anything more »